Sun Pharma Q2 profit rises 28% to ₹3,040 cr
The company’s revenue from operations increased 9% year-on-year to ₹13,291 crore for the second quarter.
The company’s revenue from operations increased 9% year-on-year to ₹13,291 crore for the second quarter.
The upfront payment of $8 per share of common stock in cash represents a premium of around 33% to Concert's 30-day volume weighted average price as of January 18, 2023.
The price of the palbociclib treatment, which used to be at least ₹50,000 a month, will come down substantially.
The pharma company received a warning letter from the U.S. FDA for violations of manufacturing standards at the Halol facility in Gujarat.
Acquisitions and product focus make Shanghvi India's wealthiest drug maker.
The BSE Sensex and the NSE Nifty ended more than 1% higher on Tuesday, led by index heavyweights such as RIL, SBI, Titan, and NTPC.